BioinvestGPT

BioinvestGPT ApS · Research use only

NCT05589610 (EQ101 in Moderate to Severe Alopecia Areata): BVCT ex-ante prediction vs. reported outcome

On 18 Feb 2024, BioinvestGPT's BVCT predicted technical success and commercial success for this trial. The 4 Jun 2024 readout is classified on the dashboard as True Positive (TP), a correct prediction. Recorded clinical-benefit conclusion: statistically significant and commercially sufficient (only one approved treatment so far).

Clinical Trial

NCTID
NCT05589610
Drug Name
EQ101
Drug MoA
tri-specific IL2/IL9/IL15 inhibitor
Drug Modality
small molecule
Drug Class
First-In-Class
Therapeutic Area
Skin and Connective Tissue Diseases
Indication
Moderate to Severe Alopecia Areata
Human Patients
36
Sponsor
Equillium
Phase
Phase 2

Prediction of , index 846

Prospective Prediction
Prediction Index
846
Prediction Date
Commercial Prediction
SUCCESS (commercially sufficient clinical benefit)
Technical Prediction
SUCCESS (statistically significant clinical benefit)

Readout of

Prediction Validation
Readout Date
Prediction To Readout
107 days in advance
Readout Data Interpretation
20-29% <20 SALT score at week 24 achieved by EQ101) (vs 23% <20 SALT score at week 24 achieved by ritlectinib 50mg King et al. 2023 Lancet in NCT03732807).
Press Release
Prediction Result
Prediction Accuracy
Correct Prediction
Clinical Benefit Conclusion
statistically significant and commercially sufficient (only one approved treatment so far)
Prediction Classification
True Positive (TP)

ClinicalTrials.gov record

ClinicalTrials.gov record, retrieved 2026-09-24. Third-party data.

Official title
An Open-label, Phase 2 Study to Assess the Safety and Efficacy of EQ101 in Adult Subjects With Moderate to Severe Alopecia Areata
Phase
Phase 2
Status
Completed
Enrollment
36
Lead sponsor
Equillium
Conditions
Alopecia Areata; Alopecia; Alopecia Totalis; Alopecia Universalis
Interventions
DRUG: EQ101
Design
Single group · None
Primary purpose
Treatment
Start
2022-12-19
Primary completion
2024-03-26
Completion
2024-04-30
Results first posted
2025-04-10
Primary outcomes
  • Number of Treatment Emergent Adverse Events (Week 28)

NCT05589610 on ClinicalTrials.gov

Return to the dashboardClinicalTrials.gov

How to read these records: evidence · methodology · all trials